[go: up one dir, main page]

TWI341200B - Telmisartan acid addition salt - Google Patents

Telmisartan acid addition salt

Info

Publication number
TWI341200B
TWI341200B TW099114822A TW99114822A TWI341200B TW I341200 B TWI341200 B TW I341200B TW 099114822 A TW099114822 A TW 099114822A TW 99114822 A TW99114822 A TW 99114822A TW I341200 B TWI341200 B TW I341200B
Authority
TW
Taiwan
Prior art keywords
acid addition
addition salt
telmisartan
telmisartan acid
salt
Prior art date
Application number
TW099114822A
Other languages
English (en)
Other versions
TW201034664A (en
Inventor
Kai Donsbach
Irmgard Hof
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI341200(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of TW201034664A publication Critical patent/TW201034664A/zh
Application granted granted Critical
Publication of TWI341200B publication Critical patent/TWI341200B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW099114822A 2001-10-31 2002-10-29 Telmisartan acid addition salt TWI341200B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels

Publications (2)

Publication Number Publication Date
TW201034664A TW201034664A (en) 2010-10-01
TWI341200B true TWI341200B (en) 2011-05-01

Family

ID=7704331

Family Applications (2)

Application Number Title Priority Date Filing Date
TW091132070A TWI333419B (en) 2001-10-31 2002-10-29 Crystalline sodium salt, process for the manufacture thereof and use thereof for the preparation of a medicament
TW099114822A TWI341200B (en) 2001-10-31 2002-10-29 Telmisartan acid addition salt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW091132070A TWI333419B (en) 2001-10-31 2002-10-29 Crystalline sodium salt, process for the manufacture thereof and use thereof for the preparation of a medicament

Country Status (34)

Country Link
EP (1) EP1442023B1 (zh)
JP (1) JP5124076B2 (zh)
KR (1) KR100929502B1 (zh)
CN (1) CN100509789C (zh)
AR (1) AR037148A1 (zh)
AT (1) ATE370125T1 (zh)
AU (1) AU2002338886B2 (zh)
BR (1) BR0213568A (zh)
CA (1) CA2463146C (zh)
CO (1) CO5580785A2 (zh)
CY (1) CY1107504T1 (zh)
DE (2) DE10153737A1 (zh)
DK (1) DK1442023T3 (zh)
EA (1) EA007596B1 (zh)
EC (1) ECSP045089A (zh)
ES (1) ES2291505T3 (zh)
HR (1) HRP20040372A8 (zh)
HU (1) HUP0402391A3 (zh)
IL (2) IL161165A0 (zh)
ME (1) MEP43608A (zh)
MX (1) MXPA04004013A (zh)
MY (1) MY129741A (zh)
NO (1) NO326465B1 (zh)
NZ (1) NZ532716A (zh)
PE (1) PE20030629A1 (zh)
PL (1) PL211462B1 (zh)
PT (1) PT1442023E (zh)
RS (1) RS50879B (zh)
SA (1) SA02230419B1 (zh)
SI (1) SI1442023T1 (zh)
TW (2) TWI333419B (zh)
UA (1) UA82833C2 (zh)
UY (1) UY27520A1 (zh)
WO (1) WO2003037876A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
CA2555294A1 (en) 2004-02-11 2005-08-25 Marina Yu Etinger Candesartan cilexetil polymorphs
KR20090029310A (ko) * 2004-05-05 2009-03-20 테바 파마슈티컬 인더스트리즈 리미티드 순도가 높은 칸데사르탄 실렉세틸의 제조
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
JP2008516001A (ja) * 2004-11-03 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 非晶質、および多形のフォームのテルミサルタン・ナトリウム
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
EP2448576A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
EA025946B1 (ru) 2010-10-27 2017-02-28 Крка, Товарна Здравил, Д. Д., Ново Место Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
EA031602B1 (ru) 2011-11-25 2019-01-31 Адверио Фарма Гмбх Способы получения альдегидов
CN111888368B (zh) 2014-10-21 2024-02-02 武田药品工业株式会社 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
US20220098197A1 (en) * 2019-01-10 2022-03-31 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Salts of heterocyclic compound and use thereof
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
US20250195525A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US6174910B1 (en) * 1996-02-29 2001-01-16 Novartis Ag AT1 receptor antagonist for the stimulation of apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
MY129741A (en) 2007-04-30
WO2003037876A1 (de) 2003-05-08
EP1442023A1 (de) 2004-08-04
EA200400479A1 (ru) 2004-10-28
NO326465B1 (no) 2008-12-08
CA2463146C (en) 2011-01-25
ATE370125T1 (de) 2007-09-15
TWI333419B (en) 2010-11-21
AU2002338886B2 (en) 2008-04-17
ECSP045089A (es) 2004-06-28
TW200300082A (en) 2003-05-16
HRP20040372A2 (en) 2004-10-31
KR100929502B1 (ko) 2009-12-03
DE10153737A1 (de) 2003-05-28
DK1442023T3 (da) 2007-11-05
JP2005536445A (ja) 2005-12-02
HUP0402391A3 (en) 2010-03-29
UA82833C2 (uk) 2008-05-26
IL161165A0 (en) 2004-08-31
EP1442023B1 (de) 2007-08-15
MEP43608A (en) 2011-02-10
UY27520A1 (es) 2003-05-30
CY1107504T1 (el) 2013-03-13
HRPK20040372B4 (hr) 2025-09-12
PT1442023E (pt) 2007-09-17
HK1073841A1 (zh) 2005-10-21
TW201034664A (en) 2010-10-01
KR20050035172A (ko) 2005-04-15
CN1578772A (zh) 2005-02-09
PL367477A1 (en) 2005-02-21
SA02230419B1 (ar) 2007-07-31
CO5580785A2 (es) 2005-11-30
BR0213568A (pt) 2004-09-08
CA2463146A1 (en) 2003-05-08
EA007596B1 (ru) 2006-12-29
DE50210719D1 (de) 2007-09-27
IL161165A (en) 2009-12-24
MXPA04004013A (es) 2004-06-18
HUP0402391A2 (hu) 2005-03-29
AR037148A1 (es) 2004-10-27
JP5124076B2 (ja) 2013-01-23
PE20030629A1 (es) 2003-07-14
HRP20040372A8 (hr) 2025-09-12
NO20041758L (no) 2004-04-29
RS50879B (sr) 2010-08-31
CN100509789C (zh) 2009-07-08
SI1442023T1 (sl) 2007-12-31
PL211462B1 (pl) 2012-05-31
ES2291505T3 (es) 2008-03-01
NZ532716A (en) 2007-06-29
HRPK20040372B3 (en) 2006-02-28
YU36304A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
HUS1900052I1 (hu) 2-acilaminotiazol-származékok vagy sóik
TWI341200B (en) Telmisartan acid addition salt
GB2392460B (en) Delayed-gelation solution
AU2003269388A8 (en) Biocidal solution
AU2002358718A1 (en) 2-heteroarylcarboxylic acid amides
PL367196A1 (en) Carboxylic acid derivative and salt thereof
ZA200500621B (en) 2-cyano-4-fluoropyrrolidine derivative or its salt
AU2002358700A8 (en) Urea derivatives as vr1- antagonists
EP1314725A4 (en) SULPHONIUMSALZ CONNECTION
EP1381270A4 (en) ANIMAL BRAND
AU2003265382A8 (en) Antibacterial benzoic acid derivatives
PL370740A1 (en) Pyridyloxyalkanoic acid amide derivatives useful as fungicides
AU2002350942A8 (en) Imidazolidineacetic acid derivatives
PL364901A1 (en) Oxalic acid derivatives
MXPA03009091A (es) Amidas novedosas del acido n-p-propargiloxifenetil-tioacetico.
EP1425258A4 (en) ANALOGUES OF HYDROXYEICOSENOIC ACID
PL362129A1 (en) Novel benzoylguanidine salt
IL157151A0 (en) Pyrrolecarboxamides for use as fungicides
HU0103064D0 (en) New polymorphic salt
GB0207286D0 (en) Salt
GB0113927D0 (en) Pooles lures
CA91072S (en) Salt platform
GB0107361D0 (en) Hydroxamic acid derivatives
GB0109553D0 (en) Hydroxamic acid derivatives
GB0109551D0 (en) Hydroxamic acid derivatives

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees